New data presented at the ECTRIMS 2024 Congress in Copenhagen shows that Temelimab rescues the neurodegenerative effects of HERV-W in an MS model
Geneva, Switzerland, September 19, 2024 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as […]
GeNeuro announces that it submits a request for a debt moratorium to the Geneva Court of First Instance
Geneva, Switzerland, July 15, 2024 – 7:00 am CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the […]
GeNeuro announces the results of the GNC-501 in post-COVID-19 syndrome
Geneva, Switzerland, June 28, 2024 – 7:00 am CEST – The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show […]
GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting
GeNeuro Announces Approval of all ResolutionsProposed at 2024 Annual General Meeting Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), […]
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024
Geneva, Switzerland, May 16, 2024 – 8.00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing therapies for patients with neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post- Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the last patient enrolled in […]
GeNeuro publishes its 2023 Universal Registration Document
Geneva, Switzerland, May 2, 2024 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID- 19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which […]
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 30, 2024 – 6.30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the […]
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
Geneva, Switzerland, March 20, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its […]
GeNeuro announces the availability of a prospectus for the listing of new shares on Euronext Paris
Geneva, Switzerland, February 2, 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (the “Company”), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, COVID long or post-COVID), announces that on February […]
GeNeuro announces a successful €5 million private placement
Geneva, Switzerland, February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital […]